Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

The FDA has approved gefurulimab (Klygefa) for adults with AChR-antibody-positive generalized myasthenia gravis — making it the first self-administered, once-weekly complement C5 inhibitor for the condition. Unlike its predecessors eculizumab and ravulizumab, which require IV infusions, Klygefa is given at home via autoinjector. The approval was backed by the phase 3 PREVAIL trial, which showed significant improvements in daily functioning and disease severity.
The FDA has approved gefurulimab (Klygefa), a novel complement C5 inhibitor from Alexion and AstraZeneca, for adults with generalized myasthenia gravis (gMG) who test positive for anti-acetylcholine receptor (AChR) antibodies. What sets it apart from the two existing C5 inhibitors — eculizumab (approved 2017) and ravulizumab (approved 2022) — is its once-weekly, self-administered subcutaneous injection via autoinjector, offering patients greater independence compared to the IV infusions required every 2–8 weeks with prior options.
The approval was supported by the phase 3 PREVAIL trial, a 26-week, placebo-controlled study in 260 adults with AChR-antibody-positive gMG. Gefurulimab outperformed placebo on both primary and key secondary endpoints, with improvements in daily functioning visible as early as week 1 and sustained through week 26. Patients on gefurulimab also needed rescue therapies like IVIG or plasmapheresis less frequently and had fewer MG-related hospitalizations.
Key Takeaways:
Why it matters: Klygefa expands the gMG treatment landscape with a first-of-its-kind at-home option, potentially improving adherence and quality of life for a large subset of patients who previously had no self-administered complement inhibitor available.